Literature DB >> 16137925

Malaria vaccines 1985-2005: a full circle?

Geoffrey A Targett1.   

Abstract

Few who were actively engaged in malaria vaccine research 20 years ago (including myself) would have imagined that, in 2005, there would still be a prediction of a 10-20-year horizon before vaccines become part of malaria-control strategies. Why is it still proving so challenging to produce effective vaccines?

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16137925     DOI: 10.1016/j.pt.2005.08.018

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  6 in total

Review 1.  Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes.

Authors:  Nicole Westerfeld; Gerd Pluschke; Rinaldo Zurbriggen
Journal:  Wien Klin Wochenschr       Date:  2006       Impact factor: 1.704

2.  Single-chain antibody fragment specific for Plasmodium vivax Duffy binding protein.

Authors:  So-Hee Kim; Seung-Young Hwang; Yong-Seok Lee; In-Hak Choi; Sae-Gwang Park; Weon-Gyu Kho
Journal:  Clin Vaccine Immunol       Date:  2007-04-25

3.  Comparative testing of six antigen-based malaria vaccine candidates directed toward merozoite-stage Plasmodium falciparum.

Authors:  David E Arnot; David R Cavanagh; Edmond J Remarque; Alison M Creasey; Mercy P K Sowa; William D Morgan; Anthony A Holder; Shirley Longacre; Alan W Thomas
Journal:  Clin Vaccine Immunol       Date:  2008-06-11

Review 4.  The role of different components of the immune system against Plasmodium falciparum malaria: Possible contribution towards malaria vaccine development.

Authors:  Wilson L Mandala; Visopo Harawa; Fraction Dzinjalamala; Dumizulu Tembo
Journal:  Mol Biochem Parasitol       Date:  2021-10-16       Impact factor: 1.759

Review 5.  Malaria vaccines and their potential role in the elimination of malaria.

Authors:  Geoffrey A Targett; Brian M Greenwood
Journal:  Malar J       Date:  2008-12-11       Impact factor: 2.979

6.  A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial.

Authors:  Shinji L Okitsu; Olivier Silvie; Nicole Westerfeld; Marija Curcic; Andreas R Kammer; Markus S Mueller; Robert W Sauerwein; John A Robinson; Blaise Genton; Dominique Mazier; Rinaldo Zurbriggen; Gerd Pluschke
Journal:  PLoS One       Date:  2007-12-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.